EXEL

Insider trade Sale by Aftab Dana (EVP, Research and Development)

4d ago

Insider trade Sale by Haley Patrick J. (EVP, Commercial)

10d ago

Insider trade Sale by Senner Christopher J. (EVP and CFO)

13d ago

Insider trade Sale by Hefti Brenda (SVP and General Counsel)

13d ago

News Why Exelixis Stock Is Skyrocketing Today

14d ago

News Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yields Eye Danger Zone: What's Driving Markets Wednesday?

14d ago

News CoreWeave, Super Micro Computer And Coinbase Are Among Top 11 Large-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio?

14d ago

News Why Exelixis Stock Trounced the Market on Thursday

14d ago

News Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?

14d ago

News Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

14d ago

News Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla

14d ago

Insider trade Sale by George Poste

24d ago

Insider trade Sale by Mary C Beckerle

24d ago

Insider trade Sale by Maria C Freire

24d ago

News Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback authorization

27d ago

News Kura rises after early-stage trial data for kidney cancer therapy

46d ago

Insider trade Sale by Dana Aftab (EVP, Research and Development)

95d ago

Insider trade Sale by Dana Aftab (EVP, Research and Development)

95d ago

News Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch

111d ago

News Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch

133d ago

News Mega-to-large cap healthcare stocks with the strongest earnings momentum

136d ago

News InSilico Lands Drug Discovery Deal After Hong Kong IPO

138d ago

News Exelixis cut to Underperform at BofA on valuation and lack of catalysts

147d ago

News Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

153d ago

News Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

153d ago